Logo for Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Investor Relations Material

Latest events

Logo for Adamis Pharmaceuticals Corporation

Q1 2023

Adamis Pharmaceuticals
Logo for Adamis Pharmaceuticals

Q3 2023

14 Nov, 2023
Logo for Adamis Pharmaceuticals

Q2 2023

21 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Adamis Pharmaceuticals Corporation

Access all reports
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company is focused on developing and commercializing products in the therapeutic areas of allergy, opioid overdose and respiratory disease. The company's product candidate includes Symjepi (previously known as APC-5000), an epinephrine syringe for self-administration by patients for emergency treatment of acute allergic reactions, including anaphylaxis. It is designed to be prefilled and ready to use immediately at the time of need. The Company's sales channels include the Pulmonary Division of Forest Laboratories, Inc., which markets Symjepi to wholesalers exclusively in the U.S.